NYSEARCA:OSTX - NYSE Arca - US68764Y2072 - Common Stock - Currency: USD
1.89
+0.03 (+1.61%)
The current stock price of OSTX is 1.89 USD. In the past month the price decreased by -37.62%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.85 | 354.98B | ||
AMGN | AMGEN INC | 15.03 | 159.99B | ||
GILD | GILEAD SCIENCES INC | 23.87 | 137.10B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1656.31 | 123.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.25 | 76.09B | ||
ARGX | ARGENX SE - ADR | N/A | 39.34B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.37B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.06B | ||
NTRA | NATERA INC | N/A | 22.20B | ||
BIIB | BIOGEN INC | 8.32 | 19.98B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.01B |
OS Therapies Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2024-08-01. OS Therapies Incorporated is a clinical-stage biopharmaceutical company. The firm is focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company built a pipeline of product candidates targeting multiple indications for solid cancers. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. OST-HER2 is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH sensitive silicone linkers (SiLinkers). The payloads can include antibodies, chemotherapeutics, cytotoxins and potentially mRNA treatments directly into and in the vicinity of solid tumors.
OS THERAPIES INC
15825 Shady Grove Road, Suite 135
Rockville MARYLAND US
Employees: 4
Company Website: https://ostherapies.com/
Phone: 14102977793
The current stock price of OSTX is 1.89 USD. The price increased by 1.61% in the last trading session.
The exchange symbol of OS THERAPIES INC is OSTX and it is listed on the NYSE Arca exchange.
OSTX stock is listed on the NYSE Arca exchange.
9 analysts have analysed OSTX and the average price target is 14.96 USD. This implies a price increase of 691.53% is expected in the next year compared to the current price of 1.89. Check the OS THERAPIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
OS THERAPIES INC (OSTX) has a market capitalization of 40.14M USD. This makes OSTX a Nano Cap stock.
OS THERAPIES INC (OSTX) currently has 4 employees.
OS THERAPIES INC (OSTX) has a support level at 1.88. Check the full technical report for a detailed analysis of OSTX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
OSTX does not pay a dividend.
OS THERAPIES INC (OSTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.36).
The outstanding short interest for OS THERAPIES INC (OSTX) is 1.83% of its float. Check the ownership tab for more information on the OSTX short interest.
ChartMill assigns a technical rating of 1 / 10 to OSTX.
ChartMill assigns a fundamental rating of 1 / 10 to OSTX. OSTX has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months OSTX reported a non-GAAP Earnings per Share(EPS) of -0.36. The EPS decreased by -40.49% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -375.2% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 82% to OSTX. The Buy consensus is the average rating of analysts ratings from 9 analysts.